AI
AXSM icon

Atom Investors’s Axsome Therapeutics AXSM Stock Holding History

Atom Investors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.47M Buy
14,179
+5,988
+73% +$1.3M 0.31% 53
2026
Q1 		$1.38M Buy
+8,191
New +$1.41M 0.1% 305
2021
Q4 		– Sell
-19,098
Closed -$629K – 277
2021
Q3 		$629K Buy
+19,098
New +$744K 0.05% 175

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atom Investors's AXSM Position: Q2 2026 in Review

Atom Investors increased its Axsome Therapeutics (AXSM) stake by 73% in Q2 2026, buying an estimated $1.3M and bringing the position to 14,179 shares worth $3.47M. The position accounts for 0.31% of the portfolio, ranked #53.

Atom Investors first reported a position in AXSM in Q3 2021 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Atom Investors held 14,179 shares of Axsome Therapeutics worth $3.47M as of Q2 2026.
  • Atom Investors bought 5,988 Axsome Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Axsome Therapeutics made up 0.31% of Atom Investors's portfolio in Q2 2026, its #53 holding.
  • Atom Investors first reported a position in Axsome Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.